OBI filled application of Phase 1 human clinical study for Novel Botulinum Toxin preparation, OBI-858, to TFDA

OBI filled application of Phase 1 human clinical study for Novel Botulinum Toxin preparation, OBI-858, to TFDA Date of occurrence of the event: Jun 10, 2020 Company name: OBI Pharma …

OBI Pharma Posters at 2020 ASCO Virtual Annual Meeting for Adagloxad Simolenin, OBI-999 and OBI-3424

Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adagloxad simolenin (OBI-822) and OBI-821 treatment in patients with early-stage triple-negative breast cancer (TNBC) at high risk …

OBI has filed application of Phase I/II human clinical studies for passive immunotherapeutic monoclonal antibody OBI-888 to TFDA

Date of occurrence of the event: May 29, 2020 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: Not …

OBI has signed a non-binding MOU to form a strategic partnership to develop novel bispecific antibody cancer treatments

Date of occurrence of the event:26 May 2020 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office Reciprocal shareholding ratios: No applicable …

OBI Pharma Announces Poster Presentations at 2020 ASCO Virtual Annual Meeting for Adagloxad Simolenin, OBI-999 and OBI-3424

Poster Presentations to highlight the ongoing clinical studies targeting Globo H and AKR1C3 antigens in different tumor types TAIPEI, Taiwan, May 20, 2020 — OBI Pharma, Inc. (TPEx: 4174), a …

Supplementary statement for 2020 Shareholders’ Meeting (Change in location and new items)

Date of the board of directors resolution:May 08, 2020 Date for convening the shareholders’ meeting:Jun 22, 2020 Location for convening the shareholders’ meeting:Courtyard Taipei, 7F Supernova Ballroom (7F, No.359, Sec. …

The active cancer immunotherapy OBI-822, Adagloxad Simolenin, has been granted by Ministry of Food and Drug Safety of South Korea to proceed Phase III human clinical study

Date of occurrence of the event: Apr 10, 2020 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office Reciprocal shareholding ratios: No …

OBI Pharma Updates on Clinical Trial Activities During COVID-19 Pandemic

TAIPEI, TAIWAN. APRIL 8, 2020– OBI Pharma has been closely monitoring the impact of the COVID-19 pandemic worldwide. We realize the intense challenges that patients and our clinical research investigators …

Due to the tense situation of Novel Coronavirus Disease (COVID-19), company decided to pause the recruitment of Global Phase III clinical study for 3 months and will restart recruitment when epidemic gets controlled.

Date of occurrence of the event: Apr 06, 2020 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office Reciprocal shareholding ratios: No …

Updates on company’s negotiable securities for investors’ information

1.Date of occurrence of the event: Mar 23, 2020 2.Cause of occurrence: Notified by Taipei Exchange (TPEx) to release information 3.Financial and business information: (1 ) Latest 1 month SUBJECT …